NeuroMetrix Management

Management Kriterienprüfungen 4/4

NeuroMetrix CEO ist Shai Gozani , ernannt in Jun 1996, hat eine Amtszeit von 28.42 Jahren. Die jährliche Gesamtvergütung beträgt $475.85K , bestehend aus 93.3% Gehalt und 6.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.68% der Aktien des Unternehmens, im Wert von $57.80K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 11.3 Jahre bzw. 13.7 Jahre.

Wichtige Informationen

Shai Gozani

Geschäftsführender

US$475.9k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	93.3%
Amtszeit als Geschäftsführer	28.4yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	11.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	13.7yrs

Jüngste Management Updates

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Shai Gozani im Vergleich zu den Einnahmen von NeuroMetrix verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$476k	US$444k	-US$7m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$645k	US$415k	-US$4m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$558k	US$415k	-US$2m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$1m
Dec 31 2020	US$181k	US$181k	-US$2m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$775k	US$422k	-US$4m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$908k
Dec 31 2018	US$478k	US$415k	US$24k
Sep 30 2018	n/a	n/a	-US$54k
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$610k	US$415k	-US$20m

Vergütung im Vergleich zum Markt: ShaiDie Gesamtvergütung ($USD475.85K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD650.80K).

Entschädigung vs. Einkommen: ShaiDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Shai Gozani (59 yo)

28.4yrs

Amtszeit

US$475,850

Vergütung

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shai Gozani	Founder	28.4yrs	US$475.85k	0.68% $ 57.8k
Thomas Higgins	Senior VP	15.2yrs	US$371.60k	0.52% $ 44.5k
Xuan Kong	Chief Data Scientist	7.4yrs	keine Daten	keine Daten
Susan Bell	Senior Vice President of Population Health & Value Based Care	3.1yrs	keine Daten	keine Daten

11.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: NURODas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (11.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shai Gozani	Founder	28.4yrs	US$475.85k	0.68% $ 57.8k
Nancy Katz	Independent Director	13.9yrs	US$105.00k	0.38% $ 31.8k
David Goodman	Independent Director	20.4yrs	US$110.00k	0.38% $ 31.8k
Arthur Vinik	Member of Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
Andrew Boulton	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
David Van Avermaete	Independent Director	11.2yrs	US$105.00k	0.38% $ 31.8k
Neil Brooks	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
David Armstrong	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
Solomon Tesfaye	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
Dan Ziegler	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
Bruce Perkins	Member of the Scientific Advisory Board	13.7yrs	keine Daten	keine Daten
Jiro Nakamura	Member of Scientific Advisory Board	10.8yrs	keine Daten	keine Daten

13.7yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: NURODie Vorstandsmitglieder sind sehr erfahren ( 13.7 ).

NeuroMetrix Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

Insufficient new directors

Senior VP recently sold US$528k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit